<DOC>
	<DOCNO>NCT03002740</DOCNO>
	<brief_summary>In population patient non-valvular atrial fibrillation ( NVAF ) , treat oral anticoagulant ( OAC ) routine clinical practice England , study describe patient treat OAC , estimate compare event rate treatment discontinuation , bleeding , healthcare resource utilisation ( HCRU ) across OAC treatment .</brief_summary>
	<brief_title>Bleeding Events Oral Anticoagulant Treatment Non-Valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>1 . Have prescription apixaban , rivaroxaban , dabigatran , VKA study period 2 . Are ≥ 18 year age index date 3 . Have ≥ 12 month computerise medical data prior index date ( date OAC initiation ) 4 . Have record AF ever prior index date 1 . Have record valvular condition consider causal AF ever prior index date 2 . Have history OACs prescribe study period ( ie , history index OAC , patient need newly prescribe either apixaban , rivaroxaban , dabigatran , VKA ) 3 . Have 1 OAC exposure start date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>